MannKind Corporation operates as a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic products such as diabetes, cancer, inflammatory, and autoimmune diseases. MannKind lead investigational product candidate is the technosphere insulin system.

Current Report (Form 8-K | Period ending 2024-05-15)

Quarterly Report (Form 10-Q | Period ending 2024-03-31)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Mannkind Corp (MNKD US)

Current Report (Form 8-K | Period ending 2024-05-15)

Quarterly Report (Form 10-Q | Period ending 2024-03-31)

Current Report (Form 8-K | Period ending 2024-05-08)

Annual Report to Security Holders (Form ARS | Period ending 2023-12-13)

Current Report (Form 8-K | Period ending 2024-04-01)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)